CLINICAL TRIALS PROFILE FOR ZEPATIER
✉ Email this page to a colleague
All Clinical Trials for ZEPATIER
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02743897 ↗ | Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients | Active, not recruiting | Merck Sharp & Dohme Corp. | Phase 1/Phase 2 | 2016-05-01 | This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation. |
| NCT02743897 ↗ | Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients | Active, not recruiting | University of Pennsylvania | Phase 1/Phase 2 | 2016-05-01 | This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation. |
| NCT02781649 ↗ | Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2016-07-20 | In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant. |
| NCT02781649 ↗ | Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients | Completed | Johns Hopkins University | Phase 4 | 2016-07-20 | In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZEPATIER
Condition Name
Clinical Trial Locations for ZEPATIER
Trials by Country
Clinical Trial Progress for ZEPATIER
Clinical Trial Phase
Clinical Trial Sponsors for ZEPATIER
Sponsor Name
